Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with malignant tumors of digestive system treated with ICIs.

Methods

Medical records from consecutive patients with malignant tumors of digestive system treated with ICIs in Peking University Cancer Hospital were retrospectively collected. Tumor growth kinetics (TGK) on immunotherapy and TGK pre-immunotherapy were collected and TGK ratio (TGKR) was calculated. Hyperprogression was defined as TGKR≥2.

Results

From August 2016 to May 2017, 25 evaluable patients were identified from

SUBMITTER: Ji Z 

PROVIDER: S-EPMC6637510 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature